Radiochemotherapy in Patients With Primary Glioblastoma Comparing Two Temozolomide Dose Regimens

Overall survival seems to be comparable in both groups, although longer follow-up and a larger group of patients are needed to corroborate these results. Lower dosing of TMZ also is associated with a more beneficial toxicity profile.